Lei Xuan, Zhang Yiming, Mao Lianghao, Jiang Pan, Huang Yumeng, Gu Jia, Tai Ningzheng
Department of Burns and Plastic Surgery, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Department of Orthopedics, Affiliated Hospital of Jiangsu University, Zhenjiang, China.
Front Oncol. 2022 Sep 23;12:819051. doi: 10.3389/fonc.2022.819051. eCollection 2022.
Substantial evidence suggests that receptor tyrosine kinases (RTKs) are overexpressed in tumors; however, few studies have focused on the prognostic value of RTKs in melanoma.
The objective of this study is to evaluate the association between overexpression of RTKs and survival in melanoma patients based on immunohistochemistry (IHC) analysis.
Our review is registered on PROSPERO (http://www.crd.york.ac.uk/PROSPERO), registration number CRD42021261460. Seven databases were searched, and data were extracted. We used IHC to measure the association between overexpression of RTKs and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and clinicopathology in melanoma patients. Pooled analysis was conducted to assess the differences between Hazard Ratios along with 95% confidence intervals.
Of 5,508 publications examined following the database search, 23 publications were included in this study, which included data from a total of 2,072 patients. Vascular endothelial growth factor receptor 2 (VEGF-R2) overexpression was associated with worse OS and DFS in melanoma. Furthermore, there was an association between OS and the expression of several RTKs, including epidermal growth factor receptor (EGFR), mesenchymal-epithelial transition factor (MET), vascular endothelial growth factor receptor 1 (VEGF-R1), and insulin-like growth factor 1 receptor (IGF-1R). There were no significant correlations between EGFR overexpression and worse DFS or PFS. EGFR overexpression was associated with worse OS cutaneous and nasal melanoma, but not uveal melanoma. However, MET overexpression was related to worse OS in both cutaneous and uveal melanoma. Furthermore, EGFR overexpression was associated with a worse OS in Europe compared to other geographic areas. Moreover, EGFR and MET overexpression showed significant prognostic value in patients with the cut-off "≥10% staining".
Our findings build concrete evidence that overexpression of RTKs is associated with poor prognosis and clinicopathology in melanoma, highlighting RTK expression has the potential to inform individualized combination therapies and accurate prognostic evaluation.
大量证据表明受体酪氨酸激酶(RTK)在肿瘤中过表达;然而,很少有研究关注RTK在黑色素瘤中的预后价值。
本研究的目的是基于免疫组织化学(IHC)分析评估RTK过表达与黑色素瘤患者生存之间的关联。
在数据库检索后审查的5508篇出版物中,本研究纳入了23篇出版物,其中包括来自总共2072名患者的数据。血管内皮生长因子受体2(VEGF-R2)过表达与黑色素瘤患者较差的OS和DFS相关。此外,OS与几种RTK的表达之间存在关联,包括表皮生长因子受体(EGFR)、间充质上皮转化因子(MET)、血管内皮生长因子受体1(VEGF-R1)和胰岛素样生长因子1受体(IGF-1R)。EGFR过表达与较差的DFS或PFS之间无显著相关性。EGFR过表达与皮肤和鼻黑色素瘤较差的OS相关,但与葡萄膜黑色素瘤无关。然而,MET过表达与皮肤和葡萄膜黑色素瘤较差的OS均相关。此外,与其他地理区域相比,欧洲EGFR过表达与较差的OS相关。此外,EGFR和MET过表达在“染色≥10%”的患者中显示出显著的预后价值。
我们的研究结果提供了确凿证据,表明RTK过表达与黑色素瘤的不良预后和临床病理相关,突出了RTK表达有可能为个体化联合治疗和准确的预后评估提供依据。